Next Article in Journal
Hypoxia PET Imaging with [18F]-HX4—A Promising Next-Generation Tracer
Previous Article in Journal
Erratum: Boland, P.M., et al. Immunotherapy for Colorectal Cancer, Cancers 2017, 9, 50
Previous Article in Special Issue
Immune Cell Subtypes and Cytokines in Lung Tumor Microenvironment: Influence of COPD
Open AccessReview

Insights into the Molecular Mechanisms Behind Intralesional Immunotherapies for Advanced Melanoma

Department of Surgery, Faculty of Medicine, Dalhousie University, Halifax, NS B3H 4R2, Canada
*
Author to whom correspondence should be addressed.
Cancers 2020, 12(5), 1321; https://doi.org/10.3390/cancers12051321
Received: 24 April 2020 / Revised: 17 May 2020 / Accepted: 20 May 2020 / Published: 22 May 2020
(This article belongs to the Special Issue Mechanism of Immunotherapy in Cancers)
The incidence of cutaneous melanoma, a highly malignant skin cancer, is increasing yearly. While surgical removal of the tumor is the mainstay of treatment for patients with locally confined disease, those with metastases face uncertainty when it comes to their treatment. As melanoma is a relatively immunogenic cancer, current guidelines suggest using immunotherapies that can rewire the host immune response to target melanoma tumor cells. Intralesional therapy, where immunomodulatory agents are injected directly into the tumor, are an emerging aspect of treatment for in-transit melanoma because of their ability to mitigate severe off-target immune-related adverse events. However, their immunomodulatory mechanisms are poorly understood. In this review, we will summarize and discuss the different intralesional therapies for metastatic melanoma with respect to their clinical outcomes and immune molecular mechanisms. View Full-Text
Keywords: in-transit melanoma; intralesional; intratumoral; interleukin-2; BCG; T-VEC; rose bengal in-transit melanoma; intralesional; intratumoral; interleukin-2; BCG; T-VEC; rose bengal
MDPI and ACS Style

Vidovic, D.; Giacomantonio, C. Insights into the Molecular Mechanisms Behind Intralesional Immunotherapies for Advanced Melanoma. Cancers 2020, 12, 1321.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop